依帕司他联合复方樟柳碱治疗NPDR的疗效  

Clinical observation on the curative effect of epalrestat combined with compound anisodine in treatment of non-proliferative diabetic retinopathy

作　　者：高秀云[1] 蔡辉耀[2] 施文建[1] 陈家欣[1] Xiu-Yun Gao;Hui-Yao Cai;Wen-Jian Shi;Jia-Xin Chen(Department of Ophthalmology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China;Department of Endocrinology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China)

机构地区：[1]福建医科大学附属第二医院眼科,福建泉州362000 [2]福建医科大学附属第二医院内分泌科,福建泉州362000

出　　处：《国际眼科杂志》2019年第6期997-1001,共5页International Eye Science

摘　　要：目的:探讨依帕司他联合复方樟柳碱治疗非增殖性糖尿病视网膜病变(NPDR)的疗效。方法:将NPDR患者随机分为A、B、C组,分别采用羟苯磺酸钙、依帕司他、依帕司他联合复方樟柳碱治疗,疗程为6mo。治疗前后行BCVA、眼底彩照、FFA、视网膜电流图的震荡电位(ERG-Ops)和OCT检查,评定治疗效果。结果:治疗前,三组患者BCVA、Ops波震幅、黄斑中心凹视网膜厚度(CMT)无差异(P>0.05)。治疗1、3、6mo后,三组患者BCVA提升,Ops波震幅上升,CMT降低(P<0.05);与A组比较,B组各时间点视力提升、Ops波震幅上升,CMT降低(P<0.05);与B组比较,C组各时间点视力提升、Ops波震幅上升,CMT降低(P<0.05)。三组治疗总有效率有差异(P<0.05),C组治疗总有效率优于B组与A组(P<0.0167)。结论:依帕司他联合复方樟柳碱治疗DR疗效肯定,可明显提高患者视力,改善黄斑水肿,促进视网膜功能恢复正常。AIM: To investigate the clinical value of epalrestat combined with compound anisodine in treatment of non-proliferative diabetic retinopathy (NPDR). METHODS: According to the random remainder method, they were divided into A, B and C three groups. Group A was treated with calcium dobesilate, group B was treated with epalrestat, and group C was treated with epalrestat combined with compound anisodine. All groups were treated for 6mo. The BCVA and fundus color photos, fundus fluorescein angiography (FFA), oscillatory potentials of electroretinogram (ERG-Ops) and optical coherence tomography (OCT) were performed before and after 1mo, 3mo and 6mo of treatment. The therapeutic effect was evaluated. RESULTS: Before treatment, there was no statistical difference among the three groups in BCVA, Ops wave amplitude or central macular thickness ( P >0.05). The BCVA was improved, Ops wave amplitude was increased and the central macular thickness was decreased in the three groups after 1mo, 3mo and 6mo of treatment. Compared with the same group before treatment, there were statistically significant differences ( P <0.05). The improvement of visual acuity at different time and the increase of Ops wave amplitude were better in group B than group A, better in group C than group B, while the decrease of central macular thickness was greater in group B than group A, greater in group C than group B (all P <0.05). The total effective rate among the three groups were significant difference ( P <0.05), and the total effective rate of group C was better than that of group B and group A ( P <0.0167). CONCLUSION: Epalrestat combined with compound anisodine is effective in treatment of DR. The combined treatment can significantly improve the visual acuity, relieve macular edema and promote the recovery of retinal function.

关 键 词：糖尿病视网膜病变 复方樟柳碱 依帕司他 羟苯磺酸钙 

分 类 号：R587.2[医药卫生—内分泌] R774.1[医药卫生—内科学]